sildenafil teva pharma
teva pharma b.v. - sildenafilis - plėvele dengtos tabletės - 20 mg - sildenafil
tenox
krka, d.d., novo mesto - amlodipinas - tabletės - 5 mg; 10 mg - amlodipine
alneta
krka, d.d., novo mesto - amlodipinas - tabletės - 10 mg; 5 mg - amlodipine
amlodipine actavis
actavis group ptc ehf. - amlodipinas - tabletės - 5 mg; 10 mg - amlodipine
amlodipine ingen pharma
sia ingen pharma - amlodipinas - tabletės - 5 mg; 10 mg - amlodipine
amlodipine medochemie
medochemie ltd. - amlodipinas - tabletės - 10 mg; 5 mg - amlodipine
cerazette
merck sharp & dohme b.v. - dezogestrelis - plėvele dengtos tabletės - 75 µg - desogestrel
silungo
norameda, uab - sildenafilis - plėvele dengtos tabletės - 20 mg - sildenafil
sildenafil g.l. pharma
g.l. pharma gmbh - sildenafilis - plėvele dengtos tabletės - 20 mg - sildenafil
clopidogrel acino
acino ag - klopidogrelis - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antitromboziniai vaistai - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.